Increased type IIA secretory phospholipase A2 expression contributes to oxidative stress in end-stage renal disease

Journal of Molecular Medicine

Volumn 88, Issue 1, 2010, Pages 75-83

  Van Der Giet, Markus ^a   Tölle, Markus ^a   Pratico, Domenico ^b   Lufft, Volkmar ^c   Schuchardt, Mirjam ^a   Hörl, Matthias P ^a   Zidek, Walter ^a   Tietge, Uwe J F ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Nephrologisches Zentrum Rendsburg Eckernförde   (Germany)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

End stage renal disease; Endothelial dysfunction; Oxidative stress; SPLA2

Indexed keywords

CYCLOOXYGENASE 2; ISOPROSTANE; PHENYLEPHRINE; REACTIVE OXYGEN METABOLITE; SECRETORY PHOSPHOLIPASE A2;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN CELL; KIDNEY DISEASE; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASOCONSTRICTION;

ADULT; ANIMALS; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION; GROUP II PHOSPHOLIPASES A2; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; OXIDATIVE STRESS;

EID: 75749110124     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-009-0543-3     Document Type: Article

References (42)

1. C Baigent K Burbury D Wheeler 2000 Premature cardiovascular disease in chronic renal failure Lancet 356 147 152 10.1016/S0140-6736(00)02456-9 1:STN:280:DC%2BD3cvjtVeisQ%3D%3D 10963260
2. TA Ikizler 2002 Epidemiology of vascular disease in renal failure Blood Purif 20 6 10 10.1159/000046979 11803153 (Pubitemid 34102502)
3. J Himmelfarb P Stenvinkel TA Ikizler RM Hakim 2002 The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 1524 1538 10.1046/j.1523-1755.2002.00600.x 1:CAS:528: DC%2BD38Xos1eksb0%3D 12371953 (Pubitemid 35286260)
4. F Locatelli B Canaud KU Eckardt P Stenvinkel C Wanner C Zoccali 2003 Oxidative stress in end-stage renal disease: an emerging threat to patient outcome Nephrol Dial Transplant 18 1272 1280 10.1093/ndt/gfg074 1:CAS:528:DC%2BD3sXks1Wqur0%3D 12808161
5. J Davignon P Ganz 2004 Role of endothelial dysfunction in atherosclerosis Circulation 109 Suppl 1 III27 III32 15198963
6. E O'Riordan J Chen SV Brodsky I Smirnova H Li MS Goligorsky 2005 Endothelial cell dysfunction: the syndrome in making Kidney Int 67 1654 1658 10.1111/j.1523-1755.2005.00256.x 15840005 (Pubitemid 40577693)
7. TJ Nevalainen MM Haapamaki JN Gronroos 2000 Roles of secretory phospholipases A2 in inflammatory diseases and trauma Biochim Biophys Acta 1488 83 90 1:CAS:528:DC%2BD3cXotlGitr8%3D 11080679
8. E Hurt-Camejo G Camejo H Peilot K Oorni P Kovanen 2001 Phospholipase A2 in vascular disease Circ Res 89 298 304 10.1161/hh1601.095598 1:CAS:528:DC%2BD3MXmsVertrc%3D 11509445
9. E Hurt-Camejo S Anderson R Standal B Rosengren P Sartipy E Stadberg B Johanses 1997 Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 300 309 1:CAS:528: DyaK2sXhvFCjsr0%3D 9081685
10. M Romano E Romano S Bjorkerud E Hurt-Camejo 1998 Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries Arterioscler Thromb Vasc Biol 18 519 525 1:CAS:528:DyaK1cXis1WrsLY%3D 9555856
11. UJF Tietge C Maugeais W Cain D Grass JM Glick FC deBeer DJ Rader 2000 Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I J Biol Chem 275 10077 10084 10.1074/jbc.275.14.10077 1:CAS:528: DC%2BD3cXisFWjs78%3D 10744687 (Pubitemid 30202058)
12. B Ivandic LW Castellani XP Wang J-H Qiao M Mehrabian M Navab AM Fogelman DS Grass ME Swanson MC deBeer F deBeer AJ Lusis 1999 Role of group II secretory phospholipase A2 in atherosclerosis. 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 Arterioscler Thromb Vasc Biol 19 1284 1290 1:CAS:528:DyaK1MXkvFaktb4%3D 10323781
13. K Kugiyama Y Ota K Takazoe Y Moriyama H Kawano Y Miyao T Sakamoto H Soejima H Ogawa H Doi S Sugiyama H Yasue 1999 Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease Circulation 100 1280 1284 1:CAS:528:DyaK1MXmsFynsb4%3D 10491371 (Pubitemid 29440119)
14. JT Daugirdas 1995 Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn Adv Ren Replace Ther 2 295 304 1:STN:280:DyaK287is1WltA%3D%3D 8591121
15. UJF Tietge KF Kozarsky MH Donahee DJ Rader 2003 A tetracycline-regulated adenoviral expression system for in vivo delivery of transgenes to lung and liver J Gene Med 5 567 575 10.1002/jgm.384 1:CAS:528:DC%2BD3sXmvFyntbo%3D 12825196 (Pubitemid 40310400)
16. JR Nofer M van der Giet M Tolle I Wolinska K von Wnuck Lipinski HA Baba UJF Tietge A Godecke I Ishii B Kleuser M Schafers M Fobker W Zidek G Assmann J Chun B Levkau 2004 HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3 J Clin Invest 113 569 581 1:CAS:528: DC%2BD2cXhsFKhsbg%3D 14966566
17. UJF Tietge D Pratico T Ding CD Funk RB Hildebrand TJ van Berkel M van Eck 2005 Macrophage-specific expression of type IIA secretory phospholipase A2 results in accelerated early atherogenesis by increasing oxidative stress in LDL-receptor deficient mice J Lipid Res 46 1604 1614 10.1194/jlr.M400469-JLR200 1:CAS:528:DC%2BD2MXotFamtbo%3D 15897607 (Pubitemid 41099327)
18. M Tolle A Pawlak M Schuchardt A Kawamura UJF Tietge S Lorkowski P Keul G Assmann J Chun B Levkau M van der Giet JR Nofer 2008 HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production Arterioscler Thromb Vasc Biol 28 1542 1548 10.1161/ATVBAHA.107.161042 18483405
19. D Pratico RK Tangirala DJ Rader J Rokach GA FitzGerald 1998 Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice Nat Med 4 1189 1192 10.1038/2685 1:CAS:528: DyaK1cXms1Ggt7g%3D 9771755 (Pubitemid 28468835)
20. T Cyrus Y Yao J Rokach LX Tang D Pratico 2003 Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor deficient mice with established vascular lesions Circulation 107 521 523 10.1161/01.CIR.0000055186.40785.C4 1:CAS:528:DC%2BD3sXmsFCqsg%3D%3D 12566360 (Pubitemid 36176798)
21. P Patrignani MR Panara A Greco O Fusco C Natoli S Iacobelli F Cipollone A Ganci C Creminon J Maclouf 1994 Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J Pharmacol Exp Ther 271 1705 1712 1:CAS:528: DyaK2MXisleks70%3D 7996488
22. K Tada M Murakami T Kambe I Kudo 1998 Induction of cyclooxygenase-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions J Immunol 161 5008 5015 1:CAS:528:DyaK1cXntVWnt78%3D 9794438
23. MJ Bidgood OS Jamal AM Cunningham PM Brooks KF Scott 2000 Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes J Immunol 165 2790 2797 1:CAS:528:DC%2BD3cXmtFOru7w%3D 10946311
24. Y Cheng M Wang Y Yu J Lawson CD Funk GA Fitzgerald 2006 Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function J Clin Invest 116 1391 1399 10.1172/JCI27540 1:CAS:528:DC%2BD28XksVWns7c%3D 16614756
25. FC deBeer PM Connell J Yu MC deBeer NR Webb DR van der Westhuyzen 2000 HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism J Lipid Res 41 1849 1857 1:CAS:528:DC%2BD3cXotFahs7o%3D
26. JK Hakala K Oorni MO Pentikainen E Hurt-Camejo PT Kovanen 2001 Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances retention of LDL to human aortic proteoglycans Arterioscler Thromb Vasc Biol 21 1053 1058 1:CAS:528:DC%2BD3MXksVaqu7s%3D 11397719
27. N Leitinger AD Watson SY Hama B Ivandic J-H Qiao J Huber KF Faull DS Grass M Navab AM Fogelman FC deBeer AJ Lusis JA Berliner 1999 Role of group II secretory phospholipase A2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids Arterioscler Thromb Vasc Biol 19 1291 1298 1:CAS:528:DyaK1MXkvFaktb8%3D 10323782
28. NR Webb MA Bostrom SJ Szilvassy DR van der Westhuyzen A Daugherty FC de Beer 2003 Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice Arterioscler Thromb Vasc Biol 23 263 268 10.1161/01.ATV.0000051701.90972.E5 1:CAS:528:DC%2BD3sXptFyrtw%3D%3D 12588769 (Pubitemid 36231938)
29. K Kugiyama Y Ota S Sugiyama H Kawano H Doi H Soejima S Miyamoto H Ogawa K Takazoe H Yasue 2000 Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris Am J Cardiol 86 718 722 10.1016/S0002-9149(00)01069-9 1:CAS:528:DC%2BD3cXmslyitrw%3D 11018189 (Pubitemid 30734924)
30. SM Boekholdt TT Keller NJ Wareham R Luben SA Bingham NE Day MS Sandhu JW Jukema JJ Kastelein CE Hack KT Khaw 2005 Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol 25 839 846 10.1161/01.ATV.0000157933.19424.b7 1:CAS:528:DC%2BD2MXitlOmtr0%3D 15692105 (Pubitemid 40463879)
31. U Landmesser H Drexler 2005 The clinical significance of endothelial dysfunction Curr Opin Cardiol 20 547 551 10.1097/01.hco.0000179821.11071.79 16234629 (Pubitemid 41565341)
32. AR Chade A Lerman LO Lerman 2005 Kidney in early atherosclerosis Hypertension 45 1042 1049 10.1161/01.HYP.0000167121.14254.a0 1:CAS:528:DC%2BD2MXkt1Oltrs%3D 15897370 (Pubitemid 40770301)
33. L Ghiadoni A Cupisti Y Huang P Mattei H Cardinal S Favilla P Rindi G Barsotti S Taddei A Salvetti 2004 Endothelial dysfunction and oxidative stress in chronic renal failure J Nephrol 17 512 519 1:CAS:528:DC%2BD2cXps1yqt78%3D 15372412
34. J Passauer F Pistrosch E Bussemaker G Lassig K Herbrig P Gross 2005 Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide J Am Soc Nephrol 16 959 965 10.1681/ASN.2004070582 1:CAS:528:DC%2BD2MXjsVWqtrw%3D 15728785 (Pubitemid 41710306)
35. ND Vaziri 2004 Oxidative stress in uremia: nature, mechanisms, and potential consequences Semin Nephrol 24 469 473 10.1016/j.semnephrol.2004.06.026 1:CAS:528:DC%2BD2cXhtVCgsrfI 15490413 (Pubitemid 39361056)
36. TA Ikizler JD Morrow LJ Roberts JA Evanson B Becker RM Hakim Y Shyr J Himmelfarb 2002 Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients Clin Nephrol 58 190 197 1:CAS:528:DC%2BD38XoslWnsbw%3D 12356187 (Pubitemid 34994045)
37. GJ Handelman MF Walter R Adhikarla J Gross GE Dallal NW Levin JB Blumberg 2001 Elevated plasma F2-isoprostanes in patients on long-term hemodialysis Kidney Int 59 1960 1966 10.1046/j.1523-1755.2001.0590051960.x 1:CAS:528:DC%2BD3MXjs1ehtLc%3D 11318969 (Pubitemid 32336813)
38. CA Hamilton MJ Brosnan M McIntyre D Graham AF Dominiczak 2001 Superoxide excess in hypertension and aging : a common cause of endothelial dysfunction Hypertension 37 529 534 1:CAS:528:DC%2BD3MXhvVSnu70%3D 11230330
39. I Kudo M Murakami 2002 Phospholipase A2 enzymes Prostaglandins Other Lipid Mediat 68-69 3 58 10.1016/S0090-6980(02)00020-5 12432908 (Pubitemid 35251864)
40. T Tazzeo J Miller LJ Janssen 2003 Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle Br J Pharmacol 140 759 763 10.1038/sj.bjp.0705482 1:CAS:528:DC%2BD3sXovVans7Y%3D 14504139 (Pubitemid 37386441)
41. V Vichai C Suyarnsesthajorn D Pttiayakhajonwut K Sriklung K Kirtikara 2005 Positive feedback regulation of COX-2 expression by prostaglandin metabolites Inflamm Res 54 163 172 10.1007/s00011-004-1338-1 1:CAS:528:DC%2BD2MXkslehsL4%3D 15883739 (Pubitemid 41175267)
42. National Kidney Foundation (1997) DOQI NKF clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation, New York, pp 42-46